RNA – Talk Bio

Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’

6 days ago talkbio0Tagged Acquisition, Avidity Biosciences, financial outlook, growth strategy, Merger, Neuromuscular Diseases, Novartis, RNA, SpinCo ', Vas Narasimhan

Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy

Flagship’s Sail Biomedicines announces second round of layoffs in 2025

3 months ago talkbio0Tagged CAR-T, eRNA, Flagship, Immunology pipeline, in vivo, layoffs, Pioneering, RNA, Sail Biomedicines

Sail Biomedicines; Flagship Pioneering; layoffs; immunology pipeline; endless RNA; eRNA; in vivo CAR-T; biotech workforce reduction

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

6 months ago talkbio0Tagged Artificial Intelligence, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

AIRNA nets $155M series B to launch clinical test of RNA editing tech

7 months ago talkbio0Tagged AIR-001, Airna, RNA, RNA Editing

RNA Editing, Airna, AIR-001, RNA

Lilly’s Lepodisiran Shows Durable Lipoprotein(a) Reduction in Phase 2 Trial

7 months ago talkbio0Tagged Cardiovascular Diseases, Interferes with, Lepodisiran, long-acting therapy, Lp(a ), RNA

lepodisiran, lipoprotein(a), Lp(a), cardiovascular disease, RNA interference, long-acting therapy

Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

8 months ago talkbio0Tagged Creatine Kinase, Del-zota, DMD, Dystrophin, exon, Muscular Dystrophy, Duchenne, production, RNA, safety profile, skipping

Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile

Daiichi turns to Nosis for AI-designed RNA delivery tech

8 months ago talkbio0Tagged Biosciences, Cells, Chronic disease, Daiichi, Nosis, Partnership, RNA, Sankyo

Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease

Eli Lilly Expands Pipeline with Strategic Deals in MASH and Cancer Therapies

9 months ago talkbio0Tagged AdvanCell, alpha therapies, Cancer Therapeutic Procedure, cardiometabolic diseases, cellular targeting, Eli, Eli Lilly, Interferes with, MASH, OliX, Radiopharmaceuticals, RNA

Eli Lilly, OliX Pharmaceuticals, AdvanCell, MASH, targeted alpha therapies, radiopharmaceuticals, RNA interference, cardiometabolic diseases, cancer treatment